Introduction
The complete androgen insensitivity syndrome (CAIS) is a main disorder of sex development (DSD), representing about 25% of all diagnoses reported in the EuroDSD registry [1] . CAIS is due to inactivating mutations or deletions in the androgen receptor (AR) gene, completely abolishing the androgenic effects on target tissues before and after birth [2] . Thus, these persons present with complete female phenotype, but male karyotype and gonads represented to hormonal active testes [2] . Diagnosis may be suspected in prepubertal children for the presence of inguinal hernia containing male gonads or in adolescent girls for primary amenorrhea [2] [3] [4] . Today, mismatch between genital appearance at birth and prenatal karyotype can be an additional feature for diagnosis [3] .
In the majority of women with CAIS, the gonads are removed due to a suspected increase of cancer risk [3] [4] [5] , even if recent data estimated that the overall prevalence of testicular malignancies in CAIS is below 1% [6] . Thus, hypergonadotropic hypogonadism is operative in such patients after surgery. It requires adequate hormonal replacement therapy (HRT) from adolescence onward in the girls operated on before puberty to assure the development of secondary sexual characteristics, i.e. breast, normal pubertal growth spurt and body proportions, adequate free fat (muscle) mass and fat mass development, optimal bone mineral mass accumulation, sex-specific psychosocial and psychosexual maturation, normal social/sexual relationships and well-being [7, 8] . HRT is also needed in females who undergo gonadectomy during or after adolescence to complete or maintain female phenotypic features and to prevent bone loss [7, 8] .
In this paper, we summarize the normal pubertal pattern in CAIS and the HRT regimens for hypogonadal persons affected by this disorder.
Spontaneous Pubertal Pattern in CAIS
Few data on spontaneous pubertal development in adolescent girls with CAIS are available ( table 1 ) [4, 9, 10] . They showed that, when gonads are not removed, the onset of puberty and peak height velocity generally occur at the same age as in normal girls, albeit some delay in the mean age at B2 has been reported [4] in comparison with normative standard [11] ( table 1 ) . The development of pubic hair, if any, seems to be slightly delayed (median age at Ph2: 14 years), while axillary hair is generally absent [2, 4] .
Zachmann et al. [9] demonstrated that pubertal growth spurt in girls with CAIS resembles, both in magnitude and timing, that of females ( table 1 ), but final height was intermediate between women (+1.4 SD) and men (-0.6 SD). Recent data in patients with CAIS and mutations in AR gene, followed from infancy to late adolescence, substantially confirmed such data, showing that mean adult height was closer to median male target height than female target height [10] . Han et al. [12] reported that the adult height of women with CAIS and removed gonads at puberty or at older age was significantly higher than those who underwent gonadectomy before puberty (172 vs. 165 cm, respectively). In the same study, the lower to upper body ratio was intermediate between that of females and males [12] .
Bone age seems to correspond better to the standards for boys than to the standards for girls [9, 13] , suggesting that chromosomal status may influence bone maturation. However, the age at appearance of the thumb sesamoid bone was consistent with average female values ( table 1 ) than male ones [10] . Thus, the lack of androgen action in utero or in early life may predispose to a female pattern of bone maturation independently from sex chromosome constitution [10] .
On the whole, available data suggest that in women with CAIS and intact gonads, bone maturation and adult height may be closer to the male than to the female pattern ( table 1 ) . It may be related to a CAIS-specific sex steroid milieu characterized by a tendency to increased estrogen levels for males but clearly reduced for females ( table 2 ) [3, 4, 14] , leading to prolonged skeletal growth [12, 15] . According to this hypothesis, the tendency to increased adult height in women with CAIS could be prevented by female-appropriate estrogen induction of puberty in adolescents without gonads [12] or some estrogen supplementation in those with intact gonads [15] , but specific trials on this matter should be done to optimize management. In addition, the gene(s) on Y chromosome may contribute to the pattern of skeletal growth and maturation in CAIS [13, 16] .
'Classic' HRT in Hypogonadal Girls with CAIS
At adolescence, adequate HRT should be administered in girls with CAIS and gonads removed in prepuberty [7, 18] . No therapy should be initiated without the fully informed consent of both the adolescent and the parents [18] . In this regard, a survey carried out in Italy demonstrated that the start of HRT is a much more troublesome passage for young women with CAIS than usually considered by physicians [D'Alberton F. et al., unpubl. data].
According to the data in table 1 , hormonal induction of puberty should usually be consistent with physiological breast development in girls. The sex steroid treatment should attempt to replicate normal 'tempo' of puberty, i.e. the velocity of the progression from one stage of pubertal maturation to the following one [11] . However, no evidence-based data are available on better hormone formulations, route of administration and doses to guide clinical practice in subjects with CAIS [7, 8, 19] .
Usually oral or transdermal estrogens are used, beginning with low doses and slowly increasing on the basis of the observed rate of pubertal stage and bone age progression ( table 3 ) [7, 8, 19] . Large differences persist among pediatric endocrinologists regarding the preferred estrogen formulation and the route of administration for pubertal induction, but oral estrogens are used more often than transdermal estrogens to induce puberty in Europe as well in the USA [20] [21] [22] . Low doses of depot 17 ␤ -estradiol have also been employed in the USA to induce puberty in girls with sex chromosome DSD (Turner's syndrome) [23] .
Some advantages of transdermal over oral estrogen formulations have been reported in normal adult women (i.e. a more physiologic mode of delivery, decreased firstpass effect and less variability in markers of hepatic metabolism, less inferences with IGF-I levels, reduced risk of thromboembolism) [24] . In adolescents with Turner syndrome, transdermal estrogens resulted in a significantly greater increase in spine bone density compared with conjugated oral estrogen [25] , while benefits on other biological systems have not been clearly found [25, 26] . At any rate, no specific trial is available for girls with CAIS.
Too high estrogen doses at puberty lead to premature closure of the epiphyses and impaired adult height [7, 20] . The optimal dose of estrogen for substitutive therapy in young adulthood is not well known [7] , thus doses and formulations often rely on individual specialist's experience more than sound guidelines, as suggested by the Italian survey in young adult women with CAIS [D'Alberton et al., unpubl. data].
There is no clear evidence of adverse events related to estrogen treatment in young females with CAIS. A small increase of the risk in myocardial infarction, stroke, breast cancer and thromboembolic disease with oral estrogen replacement therapy has been reported in adult menopausal women [27] . However, the absolute risk is likely small and these results must be considered in the appropriate context. In fact, data in aging women should not be extrapolated to adolescent and young adult subjects. A recent review concluded that untreated early ovarian failure increases the risk of osteoporosis, cardiovascular disease, dementia, cognitive decline and parkinsonism, suggesting that HRT should be administered until the average age of natural menopause [28] . In this regard, long-term trials looking at long-term risks of HRT There is no evidence that the addition of cyclic progesterone is beneficial for the well-being in women without a uterus [7, 18, 19] , but this practice is adopted by several pediatric endocrinologists in some countries, for example Italy [21] . Additional studies should be done to assess the benefits, if any, and risks of this practice.
'New' Approach to HRT in Females with CAIS
Testosterone is the main endogenous sex steroid hormone secreted by gonads in women with CAIS, exerting its effects after conversion to estrogens [2] . Thus, testosterone might be used for HRT in these females. However, one trial in 4 patients did not demonstrate that androgen therapy is preferable to 'classic' estrogen treatment in women with CAIS without gonads with regard to psychosexual functioning [29] . A well-designed trial is now in progress [30] , likely allowing more appropriate therapeutic decisions in the future.
Issue of HRT and Bone Health in CAIS
Bone mineral density (BMD) has been reported to be low in individuals with CAIS [for recent review, see 15]. Lumbar BMD was usually more affected than femoral BMD [15] . Impaired BMD has been related to gonadectomy not followed by appropriate HRT, even if defective AR action at bone level may contribute per se to the altered bone mineralization [15, 31] .
The efficacy of estrogen administration in normalizing BMD in women with complete AIS and removed gonads remains a debated issue. Albeit few longitudinally followed patients are reported, the majority of the studies did not demonstrate improvements [15] -even worse BMD values under 'classic' HRT were found [15] . A relevant improvement has been shown in a single women with CAIS by using overphysiological doses of transdermal estrogens, but lumbar BMD remained -2.0 SDS at 5 years of follow-up [32] . Taken together, these findings suggest that HRT may be able to determine a better bone status in women with CAIS and removed gonads, but likely did not normalize it [15] . Because women with CAIS and intact gonads show normal BMD [33] , other testicular hormones, obviously absent after gonadectomy as insulinlike factor 3 [34] , may be involved in bone health [15] . 
Looking to the Future
Optimal HRT for CAIS women with removed gonads remains to be better defined both regarding the regimens for induction of puberty at adolescence and respective sex steroid doses in adulthood. Since CAIS is a rare condition [2] , future multicentric international well-designed studies should address these issues. Collaborative studies should also evaluate the specific end-points of pro-andcon conservative gonadal management as well as 'new' hormonal approaches.
An additional issue that should be addressed is the definition of transition protocols from pediatric services to adult-oriented systems of care, usually involving -for women with CAIS -both obstetric-gynecology and endocrinology departments. Albeit there is very little specific information on this issue [35] , the general principles of transition are likely the same as for any chronic pediatric condition and include patient education, accessibility and specific transition services, staff training, confidentiality and consent and health promotion [36] . Young patients should be encouraged to engage with the services themselves and take a greater role in planning their own treatments [35] . The involvement of both pediatric and adult clinicians can allow for careful transfer of information and strategic planning for the future. Specific milestones during transition are disclosure of diagnosis and vaginal assessment [35] . The timing of disclosure may vary according to the psycho-sexual maturity of the individual adolescent/young adult [35, 36] . Vaginal examination can be deferred until the adolescent is contemplating sexual activity [35] .
